Quantcast

Latest Medical statistics Stories

2014-02-26 08:30:01

ROTTERDAM, Netherlands and BOSTON, Feb. 26, 2014 /PRNewswire/ -- Speed, efficiency and accuracy are vital to the success of clinical trials. With large amounts of data collected and significant room for data submission errors, there is even greater potential to disqualify participating patients or expose subjects to unnecessary risky procedures due to data errors. To address these needs in clinical trials, Cardialysis, an independent Clinical Research Organization (CRO), has...

2014-02-21 12:24:22

Analysis by the Company of Phase 3 efficacy studies of Nasal Mist Technology for Dental Anesthesia expected to be complete in the next thirty days. FORT COLLINS, Colo., Feb. 21, 2014 /PRNewswire/ -- St. Renatus, LLC, announced today that the company has completed Phase 3 clinical studies and is preparing its analysis for submission to the U.S. Food and Drug Administration (FDA). The studies tested the safety and efficacy of St. Renatus' nasal mist technology in adult and pediatric...

2014-02-19 08:32:28

LONDON, Feb. 19, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: OpportunityAnalyzer: Late-Stage Chronic Kidney Disease (CKD) - Opportunity Analysis and Forecasts to 2017 OpportunityAnalyzer: Late-Stage Chronic Kidney Disease (CKD) - Opportunity Analysis and Forecasts to 2017 Summary Late-stage chronic kidney disease (CKD), encompassing stage 4 and 5 CKD, is a disease that manifests in a host of co-morbidities. Of these, bone and mineral...

2014-02-18 23:25:00

Collaboration will create methodologies to drive improved decision-making in exploratory phase development. Reston, Virginia (PRWEB) February 18, 2014 Aptiv Solutions, a global biopharmaceutical and medical device development services company leading the adoption of innovative clinical trial approaches such as adaptive design, today announced that Novartis Pharma AG, Janssen Pharmaceuticals Inc, and Eli Lilly have joined them in co-founding the ADDPLAN DF Consortium. The members of the...

2014-02-12 04:21:06

MINNEAPOLIS, Feb. 12, 2014 /PRNewswire-USNewswire/ -- DaVita Clinical Research(®) (DCR(®)), a specialty contract research organization with services spanning the full spectrum of drug and device development, announced today that it has entered into an agreement through which Pyxant Labs Inc. will provide bioanalytical laboratory services for DCR's early clinical trials. (Logo: http://photos.prnewswire.com/prnh/20140212/DC63568LOGO) "Pyxant's proven track record and overall...

2014-02-04 12:27:27

ALMERE, The Netherlands, February 4, 2014 /PRNewswire/ -- On January 29th, 2014, Emotional Brain received the Scientific Advice letters from the European Medicines Agency (EMA) for the products Lybrido and Lybridos. The company is very pleased to announce that virtually all company proposals on the development plans for the two products were endorsed. Emotional Brain has adopted a personalized approach to medicine in the development of two drugs for the treatment of...

2014-02-03 12:29:34

RESEARCH TRIANGLE PARK, N.C., Feb. 3, 2014 /PRNewswire/ -- Dr. Renu Razdan, Vice President ACRO India and also the Chief Operating Officer, Max Neeman Medical International welcomes the new timelines and guidelines set up by the Drug Controller General of India [DCGI] for approval of clinical trials. The Drug regulatory authority in India has provided written confirmation to the pharmaceutical industry and Investigators that, clinical trial approval will be given within 180 days of...

2014-01-31 23:03:19

SureTrial® eTMF’s rapid cloud deployment, ease-of-use, and unique medical imaging support for clinical trials is helping leading dermatology products companies win FDA clearance. The successful deployment and FDA approval by users of SureTrial eTMF cloud is further proof that BioPharma companies are increasingly automating manual paper-based clinical trial approaches with SureClinical’s SureTrial eTMF cloud application. Rancho Cordova, CA (PRWEB) January 31, 2014 SureClinical,...

2014-01-31 12:25:34

DUBLIN, January 31, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/nl7858/medical_device) has announced the addition of the "Medical Device: Clinical Development Market Assessment" [http://www.researchandmarkets.com/research/nl7858/medical_device ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The report provides the medical device industry and its service providers with a new...

2014-01-27 08:27:50

Latest Data from Large Subgroup of Patients Shows that the Combination of ThermoDox® and Optimized RFA Provides a Statistically Significant Survival Improvement of Over 50% LAWRENCEVILLE, N.J., Jan. 27, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) today announced that the latest overall survival data from its post-hoc analysis of results from the Company's Phase III HEAT Study of ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin in...


Word of the Day
blee
  • Color; hue; complexion.
This word is Middle English in origin.
Related